Страна: Ирландия
Язык: английский
Источник: HPRA (Health Products Regulatory Authority)
Cholecalciferol; Calcium
Imbat Limited
A12AX
Cholecalciferol; Calcium
500mg/800 international unit(s)
Chewable tablet
Product subject to prescription which may be renewed (B)
Calcium, combinations with vitamin D and/or other drugs
Authorised
2015-01-16
Page 1 of 2 PACKAGE LEAFLET: INFORMATION FOR THE USER KALCIPOS ® -D FORTE 500 MG/800 IU CHEWABLE TABLETS calcium/cholecalciferol (Vitamin D 3 ) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Kalcipos-D forte is and what it is used for 2. What you need to know before you take Kalcipos-D forte 3. How to take Kalcipos-D forte 4. Possible side effects 5. How to store Kalcipos-D forte 6. Contents of the pack and other information 1. WHAT KALCIPOS-D FORTE IS AND WHAT IT IS USED FOR Kalcipos-D forte is used to prevent and treat calcium and vitamin D 3 deficiency in the elderly, and as an additional treatment in the management of osteoporosis, when a risk of deficiency of calcium and vitamin D 3 is suspected. Kalcipos-D forte contains calcium and vitamin D 3 which both are important components for the formation of bone. Vitamin D 3 regulates the uptake and metabolism of calcium as well as the incorporation of calcium in bone tissue. Ask your doctor, pharmacist or other health personal if you have further questions and always follow their instructions. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE KALCIPOS-D FORTE DO NOT TAKE KALCIPOS-D FORTE if you have hypercalcaemia (increased levels of calcium in the blood) or hypercalciuria (increased levels in the urine). if you have kidney stones if you have calcium depositions in the kidneys if you have hypervitaminosis D (increased levels of vitamin D in the blood). if you have severely impaired kidney function/kidney failure if you Прочитать полный документ
Health Products Regulatory Authority 23 January 2019 CRN008PT1 Page 1 of 3 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Kalcipos-D forte 500 mg/800 IU chewable tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each chewable tablet contains calcium carbonate equivalent to 500mg calcium and cholecalciferol 20 microgram corresponding to 800 IU Vitamin D3. Excipients of known effect: glucose 200mg and sucrose 1.8mg. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Chewable Tablet _Product imported from the UK_ White to off-white, round, chewable tablet engraved R152 on one side, diameter 17 mm. 4 CLINICAL PARTICULARS As per PA1051/008/002 5 PHARMACOLOGICAL PROPERTIES As per PA1051/008/002 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Liquid spray dried glucose Magnesium stearate Sodium citrate Xylitol All-_rac-_alfa-tocoferol Acacia Sodium laurilsulphate Sucrose Medium chain triglycerides Starch sodium octenyl succinate (E1450) Health Products Regulatory Authority 23 January 2019 CRN008PT1 Page 2 of 3 Silicon dioxide sodium ascorbate 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf life expiry date of this product shall be the date shown on the container and outer package of the product as marketed in the country of origin. Shelf-life after first opening container: 6 months 6.4 SPECIAL PRECAUTIONS FOR STORAGE Store in the original container, in order to protect from light. Keep container tightly closed in order to protect from moisture. 6.5 NATURE AND CONTENTS OF CONTAINER Plastic container with screw cap Pack size: 30 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL OF A USED MEDICINAL PRODUCT OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCT AND OTHER HANDLING OF THE PRODUCT No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER Imbat Limited Unit L2 North Ring Business Park Santry Dublin 9 Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA1151/162/001 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 16 th Jan Прочитать полный документ